Acute Pulmonary Injury in Hematology Patients Supported with Pathogen Reduced and Conventional Platelet Components

By sjmartinez • March 7, 2024

Wheeler AP, Snyder EL, Refaai MA, Cohn CS, Poisson J, Fontaine MJ, Sehl M, Nooka AK, Uhl L, Spinella PC, Fenelus M, Liles DK, Coyle T, Becker J, Jeng MR, Gehrie EA, Spencer BR, Young PP, Johnson AD, O'Brien J, Schiller GJ, Roback JD, Malynn E, Jackups R, Avecilla S, Liu K, Bentow S, Varrone J, Benjamin RJ, Corash L. Acute Pulmonary Injury in Hematology Patients Supported with Pathogen Reduced and Conventional Platelet Components. Blood Adv. 2024 Mar 6:bloodadvances.2023012425. doi: 10.1182/bloodadvances.2023012425. Epub ahead of print. PMID: 38447116.

Tags: Hematology/Oncology, Publications

Related Posts

Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib

Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, Vasilopoulos A, Brunsdon P, Hoffman D, Shi W, Bolotin E, Blot V, Goldman[...]

ZNFX1 functions as a master regulator of epigenetically induced pathogen mimicry and inflammasome signaling in cancer

Stojanovic L, Abbotts R, Tripathi K, Coon CM, Rajendran S, Abbasi Farid E, Hostetter G, Guarnieri JW, Wallace DC, Liu S, Wan J, Calendo G,[...]

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka[...]